安旭生物 (688075.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

26.7x

Market Cap

CNY 3.70B

MomentumView details →

1D Return

−1.59%

YTD Return

—

RSI (14)

49.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

26.7x

Market Cap

CNY 3.70B

RSI (14)

49.6

MomentumView details →

1D Return

−1.59%

YTD Return

—

ProfitabilityView details →

Gross Margin

42.26%

Net Margin

6.15%

EBITDA Margin

29.70%

ROE (TTM)

0.49%

ROA (TTM)

0.43%

Asset Turnover

0.07x

GrowthView details →

Revenue YoY

−22.68%

EPS YoY

−83.72%

FCF YoY

—

Revenue CAGR 3Y

−58.17%

EPS CAGR 3Y

−71.58%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

8.87x

Quick Ratio

8.61x

Div Yield

2.73%

Div Rate

CNY 0.80

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

407.16M

Net Income (TTM)

25.03M

Op. CF (TTM)

−1.38M

Latest newsMore news →

Anxu Bio announced that as of August 31, 2026, it had repurchased 707,939 shares (0.5571% of total shares) for a total of 25.3445 million yuan under its ongoing buyback program.3d ago

Anxu Bio reported a net loss of 10.6413 million yuan for the first half of 2026, turning from a profit in the same period last year.8d ago

Similar companies

东方生物688298.SH 健麾信息605186.SH Jenscare Scientific Co., Ltd.09877.HK 祥生医疗688358.SH 普门科技688389.SH Ekso Bionics Holdings, Inc. Common StockCHRN Find similar companies →

Latest newsMore news →

Anxu Bio announced that as of August 31, 2026, it had repurchased 707,939 shares (0.5571% of total shares) for a total of 25.3445 million yuan under its ongoing buyback program.3d ago Anxu Bio reported a net loss of 10.6413 million yuan for the first half of 2026, turning from a profit in the same period last year.8d ago